Drug Profile
OBI 833
Alternative Names: Globo H-CRM 197; OBI-833; OBI-833/OBI-821Latest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator Academia Sinica
- Developer OBI Pharma
- Class Antineoplastics; Cancer vaccines; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Non-small cell lung cancer
- No development reported Solid tumours
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Second-line therapy or greater) in Taiwan (SC, Injection)
- 27 Jul 2022 Phase-II clinical trials in Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Taiwan (unspecified route) (NCT05442060)
- 01 Jul 2022 OBI Pharma plans a phase II trial for Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in June 2022 (SC) (NCT05442060)